Codexis (NASDAQ:CDXS) Rating Increased to Sell at BidaskClub

Codexis (NASDAQ:CDXS) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports.

Separately, Zacks Investment Research cut Codexis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Codexis currently has an average rating of “Buy” and a consensus target price of $20.50.

Shares of CDXS opened at $15.82 on Wednesday. The firm has a market capitalization of $911.71 million, a PE ratio of -75.33 and a beta of -0.01. The stock has a 50 day simple moving average of $14.86 and a 200 day simple moving average of $15.72. The company has a debt-to-equity ratio of 0.25, a quick ratio of 7.34 and a current ratio of 7.37. Codexis has a 52-week low of $12.68 and a 52-week high of $22.49.

Codexis (NASDAQ:CDXS) last released its earnings results on Tuesday, November 5th. The biotechnology company reported $0.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.10. The firm had revenue of $21.91 million for the quarter, compared to analysts’ expectations of $16.56 million. Codexis had a negative return on equity of 15.24% and a negative net margin of 17.85%. Equities research analysts predict that Codexis will post -0.2 EPS for the current fiscal year.

In other Codexis news, Director Thomas R. Baruch sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $15.61, for a total value of $273,175.00. Following the sale, the director now owns 90,540 shares in the company, valued at approximately $1,413,329.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDXS. FMR LLC raised its stake in shares of Codexis by 25.6% during the 1st quarter. FMR LLC now owns 917,537 shares of the biotechnology company’s stock worth $18,837,000 after purchasing an additional 187,000 shares in the last quarter. Strs Ohio raised its stake in shares of Codexis by 5.5% during the 2nd quarter. Strs Ohio now owns 42,100 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 2,200 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Codexis by 135.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 782,933 shares of the biotechnology company’s stock worth $14,429,000 after purchasing an additional 449,868 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Codexis during the 2nd quarter worth approximately $190,000. Finally, First Trust Advisors LP bought a new stake in shares of Codexis during the 2nd quarter worth approximately $2,855,000. Hedge funds and other institutional investors own 89.40% of the company’s stock.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Further Reading: Why Invest in Dividend Achievers?

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.